{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:32:00Z","timestamp":1793640720464,"version":"4.5.1"},"reference-count":21,"publisher":null,"issue":"10","license":[{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>\n                    <jats:italic>Aim\u00a0\u00a0\u00a0\u00a0\u00a0<\/jats:italic>\n                    To evaluate the effect of combination ivabradine-containing therapy for chronic heart failure (CHF) with preserved ejection fraction on quality of life (QoL) and the primary composite endpoint during a one-year follow-up.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Material and methods\u00a0<\/jats:italic>\n                    This study included 160 patients aged 45 to 65 years with NYHA functional class (FC) II-III CHF with preserved left ventricular ejection fraction (CHF-PEF) and grade I and II diastolic dysfunction associated with FC III stable angina with sinus rhythm and a heart rate (HR) higher than 70 bpm. Presence of CHF-PEF was confirmed by results of echocardiography and myocardial tissue Doppler imaging. During one year of prospective observation, effects of bisoprolol and ivabradine as a part of the combination therapy on the primary composite endpoint, including death from cardiovascular complications (CVC) and hospitalizations for myocardial infarction (MI) or CHF, were evaluated in patients with CHF-PEF. Patients were randomized to three groups: A, bisoprolol with dose titration from 2.5 to 10\u2008mg; \u0412, combination of bisoprolol 2.5-10\u2008mg and ivabradine 10-15\u2008mg\/day; and \u0421, ivabradine 10-15\u2008mg\/day. All patients were on a chronic background therapy, including angiotensin-converting enzyme inhibitors (lisinopril) or, if not tolerated, angiotensin II receptor blockers (valsartan), antiaggregants, statins (atorvastatin, rosuvastatin), and short-acting nitrates as required. If edema developed diuretics were added. The follow-up duration was one year.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results<\/jats:italic>\n                    After 12 weeks of follow-up, the achievement of goal HR in group A was associated with a tendency to increased distance in the 6-min walk test from 279\u00b119 to 341\u00b121\u2008m (\u0440&gt;0,05); in group B the distance increased from 243\u00b125 to 319\u00b129\u2008m (\u0440&lt;0.05); and in group C the distance increased from 268\u00b121 to 323\u00b122\u2008m (\u0440&lt;0.05). In the combination ivabradine and bisoprolol treatment group, results of the 24-h electrocardiogram monitoring showed a more pronounced anti-ischemic effect associated with a decrease in the number of myocardial ischemic episodes (p&lt;0.05). QoL was evaluated with the Minnesota questionnaire against the background of treatment. At 12 weeks of observation, the total score decreased from 44.5\u00b12.6 to 38.4\u00b12.1 in group A; from 45\u00b12.9 to 38\u00b12.2 in group B; and from 50.9\u00b13.2 to 42.7\u00b12.8 in group C (\u0440&lt;0.05). The risk of acute MI and repeated hospitalization for CHF during the year of observation, as evaluated according to the Kaplan-Meier method, decreased in both bisoprolol and ivabradine combination treatment groups.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion\u00a0\u00a0\u00a0\u00a0\u00a0<\/jats:italic>\n                    The inclusion of bisoprolol and ivabradine into the background therapy of CHF-PEF patients with stable IHD provided an improvement of QoL and a decrease in the risk of hospitalization for acute MI and CHF during the year of observation.\n                  <\/jats:p>\n                  <jats:p>\u00a0<\/jats:p>","DOI":"10.18087\/cardio.2020.10.n1324","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T03:28:18Z","timestamp":1606188498000},"page":"33-37","source":"Crossref","is-referenced-by-count":3,"title":["Ivabradine for Treatment of Heart Failure with Preserved Ejection Fraction"],"prefix":"10.68900","volume":"60","author":[{"given":"G. V.","family":"Babushkina","sequence":"first","affiliation":[{"name":"Institution of Higher Education \"Bashkir State Medical University\" of the Ministry of Healthcare of the Russian Federation, Ufa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. I.","family":"Shaikhlislamova","sequence":"additional","affiliation":[{"name":"State Budgetary Institution of Health Care of the Republic of Bashkortostan City Clinical Hospital \u211613, Ufa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2020,11,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129\u2013200. DOI: 10.1093\/eurheartj\/ehw128","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137\u201346. DOI: 10.1136\/hrt.2003.025270","DOI":"10.1136\/hrt.2003.025270"},{"key":"ref3","unstructured":"Rekomendatsii ESC po diagnostike i lecheniyu ostroi i khronicheskoi serdechnoi nedostatochnosti 2016. Rossiiskii Kardiologicheskii Zhurnal. 2017;22(1):7\u201381]"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Filippatos G, Parissis JT. Heart failure diagnosis and prognosis in the elderly: the proof of the pudding is in the eating. European Journal of Heart Failure. 2011;13(5):467\u201371. DOI: 10.1093\/eurjhf\/hfr036","DOI":"10.1093\/eurjhf\/hfr036"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"van Riet EES, Hoes AW, Limburg A, Landman MAJ, van der Hoeven H, Rutten FH. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion: Unrecognized HF in older persons with shortness of breath on exertion. European Journal of Heart Failure. 2014;16(7):772\u20137. DOI: 10.1002\/ejhf.110","DOI":"10.1002\/ejhf.110"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Maggioni AP, Dahlstr\u00f6m U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESCHF Pilot). European Journal of Heart Failure. 2013;15(7):808\u201317. DOI: 10.1093\/eurjhf\/hft050","DOI":"10.1093\/eurjhf\/hft050"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Oshchepkova E.V., Lazareva N.V., Satlykova D.F., Tereshchenko S.N. Pervye rezul'taty Rossiiskogo registra khronicheskoi serdechnoi nedostatochnosti. Kardiologiya. 2015;55(5):22\u20138","DOI":"10.18565\/cardio.2015.5.22-28"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Van Riet EES, Hoes AW, Wagenaar KP, Limburg A, Landman MAJ, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review: Prevalence of heart failure and ventricular dysfunction. European Journal of Heart Failure. 2016;18(3):242\u201352. DOI: 10.1002\/ejhf.483","DOI":"10.1002\/ejhf.483"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Boonman-de Winter LJM, Rutten FH, Cramer MJM, Landman MJ, Liem AH, Rutten GEHM et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55(8):2154\u201362. DOI: 10.1007\/s00125-012-2579-0","DOI":"10.1007\/s00125-012-2579-0"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Maga\u00f1a-Serrano JA, Almahmeed W, Gomez E, Al-Shamiri M, Adgar D, Sosner P et al. Prevalence of Heart Failure With Preserved Ejection Fraction in Latin American, Middle Eastern, and North African Regions in the I PREFER Study (Identification of Patients With Heart Failure and PREserved Systolic Function: An Epidemiological Regional Study). The American Journal of Cardiology. 2011;108(9):1289\u201396. DOI: 10.1016\/j.amjcard.2011.06.044","DOI":"10.1016\/j.amjcard.2011.06.044"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"B\u00f6hm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. The Lancet. 2010;376(9744):886\u201394. DOI: 10.1016\/S0140-6736(10)61259-7","DOI":"10.1016\/S0140-6736(10)61259-7"},{"key":"ref12","unstructured":"Perepech N.B. Zachem nado umen'shat' chastotu serdechnykh sokrashchenii u bol'nykh khronicheskoi serdechnoi nedostatochnost'yu? Meditsinskii Sovet. 2013;9:82\u201391"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of Randomized Controlled Trials on the Effect of Magnitude of Heart Rate Reduction on Clinical Outcomes in Patients With Systolic Chronic Heart Failure Receiving Beta-Blockers. The American Journal of Cardiology. 2008;101(6):865\u20139. DOI: 10.1016\/j.amjcard.2007.11.023","DOI":"10.1016\/j.amjcard.2007.11.023"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Borer JS, B\u00f6hm M, Ford I, Robertson M, Komajda M, Tavazzi L et al. Efficacy and Safety of Ivabradine in Patients With Severe Chronic Systolic Heart Failure (from the SHIFT Study). The American Journal of Cardiology. 2014;113(3):497\u2013503. DOI: 10.1016\/j.amjcard.2013.10.033","DOI":"10.1016\/j.amjcard.2013.10.033"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"B\u00f6hm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology. 2013;102(1):11\u201322. DOI: 10.1007\/ s00392-012-0467-8","DOI":"10.1007\/s00392-012-0467-8"},{"key":"ref16","unstructured":"Ageev F. T. Diastolicheskaya serdechnaya nedostatochnost': 10 let znakomstva. Zhurnal Serdechnaya Nedostatochnost'. 2010;11(1):69\u201376"},{"key":"ref17","unstructured":"Vasyuk Yu.A. Rukovodstvo po funktsional'noi diagnostike v kardiologii. Sovremennye metody i klinicheskaya interpretatsiya. \u2013 M.: Prakticheskaya meditsina, 2012. \u2013162s. ISBN 978-5-98811-223-4"},{"key":"ref18","unstructured":"Rector TS, Kubo SH, Cohn JN. Patients self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, the Minnesota living with heart failure questionnaire. Heart failure. 1987;10:198\u2013209"},{"key":"ref19","unstructured":"Zhubrina E.S., Ageev F.T. Beta-adrenoblokatory - vozmozhnosti optimizatsii terapii khronicheskoi serdechnoi nedostatochnosti v ambulatornykh usloviyakh Lechashchii vrach. 2013;3:80"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2012;33(14):1787\u2013847. DOI: 10.1093\/eurheartj\/ehs104","DOI":"10.1093\/eurheartj\/ehs104"},{"key":"ref21","unstructured":"Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372(9641):807\u201316. DOI: 10.1016\/S0140- 6736(08)61170-8"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/1324\/824","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:16:45Z","timestamp":1793639805000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/1324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":21,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,11,13]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2020.10.n1324","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,13]]}}}